Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Codexis has signed two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals (Dishman) and AMPAC Fine Chemicals (AFC), a subsidiary of American Pacific Corporation.
Subscribe to our email newsletter
The agreements are expected to expand the application of Codexis’ technology to a broadened pipeline of branded innovator pharmaceutical products.
As per the new agreements, Codexis will apply its proprietary biocatalyst technology to selected therapeutic products in the collaborators’ portfolios to reduce cost, increase manufacturing efficiency and lessen environmental impact. Codexis technology is used at pharmaceutical companies to enable cost-effective manufacturing processes at commercial scale.
Under the terms of the agreement, Codexis and Dishman will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators; Dishman will be Codexis’ preferred CMO partner for new opportunities at other innovators.
Alan Shaw, president and CEO, said: “These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products. They will be important as we continue to serve our pharmaceutical customers worldwide.”